Market Overview

UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity Financing Dilution

Related EXEL
Mid-Day Market Update: ON Semiconductor Surges On $1 Billion Buyback Plan; POZEN Shares Slip
Mid-Morning Market Update: Markets Open Lower; Weatherford To Sell Engineered Chemistry, Drilling Fluid Operations to Berkshire's Lubrizol

Piper Jaffray reiterated its Neutral rating on Exelixis (NASDAQ: EXEL) and reduced its price target from $5.50 to $4.50.

Piper Jaffray said, "Exelixis raised net proceeds of $120 million by issuing 30 million shares at $4.25 and $250 million from a 4.25% convertible note bringing proforma cash to $665 million. Cabozantinib has a November 29th PDUFA date in medullary thyroid cancer (MTC). Both the COMET-1 and COMET-2 pivotal studies are underway in castrate resistant prostate cancer (CRPC) plus 11 investigator sponsored trials (ISTs) under a CRADA funded by the NCI. … We are trimming our price target to $4.50 from $5.50 to account for dilution from the deals."

Exelixis closed at $4.38 on Friday.

Latest Ratings for EXEL

DateFirmActionFromTo
Sep 2014Stifel NicolausDowngradesBuyHold
Sep 2014Cowen & CompanyDowngradesOutperformMarket Perform
Sep 2014Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for EXEL
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (EXEL)

Around the Web, We're Loving...

Get Benzinga's Newsletters